| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXO39 |
| Uniprot No | Q8N4B4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-442aa |
| 氨基酸序列 | MDEESELIQPQDQSCWAFLPDLCLCRVFWWLGDRDRSRAALVCRKWNQMMYSAELWRYRTITFSGRPSRVHASEVESAVWYVKKFGRYLEHLEVKFMNPYNAVLTKKFQVTMRGLLSCLSKSNNRLKSLSIQYLELDRLVWRNSIRSSFISSLSFFLKKMGKRLDYLNLKGARLTVEQGCQILDSLSYMRNENVISELNIEDYFSHHLAVYNSPQFKKTMSTFHNLVSLNLNYNCISDELLENLCENASTLRTINIKCHVHDPHGQVIWGMSWAKLARQATNLKVNFFFERIMKYERLARILLQEIPIRSISLRSCYFSDPDCSMRPTLIDLLPTFRHTLQKLTCEFNNNHESLDEELHLLIISCRKLFYFKIWAFLDVSFVERILKSQKERQCALRVFKARIYTNRYETNEEDKTLQEIYRKYRKLIESELSYFVIVYSVM |
| 分子量 | 74.14 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与重组人FBXO39蛋白相关的参考文献示例(基于已有研究主题的合理归纳，仅供参考)：
1. **《FBXO39 mediates degradation of the mitotic phosphatase CDC14B to regulate cell cycle progression》**
- 作者：Li et al. (2022)
- 摘要：研究报道了重组人FBXO39蛋白通过泛素化降解细胞周期调控因子CDC14B，影响有丝分裂进程的机制。实验通过体外表达纯化FBXO39.证实其与SCF复合体结合并介导底物特异性识别。
2. **《Structural insights into the substrate recognition of FBXO39 in DNA damage response》**
- 作者：Wang et al. (2020)
- 摘要：通过晶体学解析重组人FBXO39蛋白的结构，揭示其F-box和C端结构域在识别DNA损伤相关底物(如BRCA1)中的作用，为癌症治疗潜在靶点提供依据。
3. **《FBXO39 promotes tumor metastasis via ubiquitination of E-cadherin in breast cancer》**
- 作者：Zhang et al. (2019)
- 摘要：利用重组FBXO39蛋白进行体外泛素化实验，证明其通过降解E-cadherin蛋白诱导上皮-间充质转化(EMT)，从而促进乳腺癌转移。
4. **《Functional characterization of recombinant human FBXO39 in viral immune escape》**
- 作者：Kim et al. (2021)
- 摘要：研究表明重组FBXO39蛋白可与病毒蛋白(如HCV核心蛋白)相互作用，通过调控NF-κB信号通路抑制宿主抗病毒免疫应答。
**注**：以上文献信息为假设性示例，实际研究中可能需根据具体数据库(如PubMed、Web of Science)检索真实文献。
Recombinant human FBXO39 protein is a biologically engineered form of the F-box domain-containing protein 39. a member of the F-box protein family. These proteins are critical components of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex, which mediates substrate recognition and subsequent ubiquitination, targeting specific proteins for proteasomal degradation. FBXO39. characterized by its F-box domain, facilitates interaction with SKP1. linking substrate adaptors to the core ligase machinery. While its exact physiological roles remain under investigation, studies suggest involvement in cellular processes such as cell cycle regulation, DNA damage response, and immune signaling. Dysregulation of FBXO39 has been preliminarily linked to diseases, including cancer and neurodegenerative disorders, with altered expression observed in certain tumor types.
The recombinant form is typically produced via bacterial or mammalian expression systems, enabling biochemical and functional studies. Researchers utilize it to dissect interactions with binding partners, substrate specificity, and regulatory mechanisms, aiming to elucidate its role in ubiquitination pathways. Structural analyses of recombinant FBXO39 also aid in mapping functional domains and mutations associated with disease.
Current research focuses on uncovering FBXO39's biological significance and therapeutic potential, particularly in targeting dysregulated ubiquitination processes in pathologies. However, comprehensive mechanistic insights and in vivo validation are still needed to fully understand its contributions to cellular homeostasis and disease progression.
×
